The civic record
Read. Follow. Verify.Montana Legislature requests interim study on COVID-19 medical response and treatments
Last action · May 23, 2025: (S) Died in CommitteeSponsor: Barry Usher
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
Montana lawmakers direct an interim committee or legislative staff to study the short-term and long-term effects of federal COVID-19 medical responses, including vaccines, remdesivir, dexamethasone, and ivermectin, with final results reported to the 70th Legislature by September 15, 2026.
Directs state legislative resources and interim committees to review past pandemic medical guidelines, federal treatment incentives, and the outcomes of the .
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Montana Legislature
Receives the final study results and recommendations prior to the 70th Legislature.
Legislative Council
Tasked with designating an appropriate interim or statutory committee or directing staff resources to conduct the study.
Key Facts
- The resolution requests an interim committee or staff review of the short-term and long-term effects of COVID-19 vaccines, remdesivir, dexamethasone, and other questionable drugs and treatments.
- The study is mandated to examine the benefits of ivermectin as a treatment for COVID-19.
- The study will examine outcomes of the Montana Right to Try Act regarding experimental treatments for active infections, long COVID, and mitigating impacts of vaccines and federally recommended treatments.
- All aspects of the study must be concluded prior to September 15, 2026.
Show all 5 facts
- Final results, findings, conclusions, comments, or recommendations must be reported to the 70th Legislature.
Frequently Asked Questions
What topics will the interim study cover regarding COVID-19?
When must the study be completed?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently passed chamber. The next step in the legislative lifecycle is Law.
Procedural history
17 actions- May 23, 2025SenateCommittee(S) Died in Committee
- Apr 24, 2025Senate(S) Motion
- Apr 23, 2025SenateCommittee(S) Tabled in Committee
- Apr 23, 2025Senate(S) Hearing
- Apr 23, 2025SenateCommittee(S) Referred to Committee
- Apr 22, 2025Senate(S) 1st Reading
Show 11 earlier actions
- Apr 22, 2025SenateIntroduced(S) Introduced
- Apr 22, 2025House(LC) Draft Delivered to Requester
- Apr 22, 2025House(LC) Draft Ready for Delivery
- Apr 21, 2025House(LC) Draft in Assembly
- Apr 21, 2025House(LC) Draft in Final Drafter Review
- Apr 21, 2025House(LC) Draft in Input/Proofing
- Apr 18, 2025House(LC) Draft in Edit
- Apr 17, 2025House(LC) Draft in Legal Review
- Apr 8, 2025House(LC) Draft Taken Off Hold
- Nov 11, 2024House(LC) Draft On Hold
- Nov 11, 2024House(LC) Drafter Assigned
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Connected Entities
Sources
bills.legmt.gov
Analysis Score
0–100- Significance35How much this matters to a regular citizen
- Controversy65Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz20Current news / social attention level
Publisher tools
